Sedana Medical presents post hoc analysis at ISICEM

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that a post hoc analysis on the Sedaconda study will be presented as a poster at the world’s largest conference for intensive care and emergency medicine, ISICEM, in Brussels on March 22-25, 2022. The company will also host a symposium at the conference.

The poster “ICU-free and ventilator-free days with Isoflurane or Propofol as a primary sedative – a post hoc analysis of the Sedaconda study” concludes that isoflurane sedation as the primary sedative during mechanical ventilation in the first 30 days after randomisation, was associated with significantly more ICU-free days than propofol sedation, with a difference of four days. The findings support the use of isoflurane as a sole sedative in patients with need for prolonged sedation.

“The positive results of this post hoc analysis strengthen the clinical evidence base for inhaled sedation further and confirm earlier retrospective studies. These results were also an important part of the documentation on which the UK’s National Institute for Health and Care Excellence (NICE) based its recommendation for Sedaconda ACD earlier this year,” said Johannes Doll, CEO of Sedana Medical.

At the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Sedana Medical will also host a scientific symposium called “Introducing inhaled sedation to intensive care”. As part of the symposium, one of the investigators of the Sedaconda study, Privatdozent Jan Wallenborn, MD PhD, will present the Sedaconda study.

The full poster is available on www.isicem.org

For additional information, please contact:
Johannes Doll, CEO, +46 76 303 66 66
ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer med tech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.